PCM
RMD icon

Portolan Capital Management’s ResMed RMD Stock Holding History

Portolan Capital Management’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-45,745
Closed -$2.15M – 150
2013
Q4 		$2.15M Buy
+45,745
New +$2.32M 0.48% 80

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Portolan Capital Management's RMD Position: Q1 2014 in Review

Portolan Capital Management sold out of ResMed (RMD) in Q1 2014, closing a stake of 45,745 shares — an estimated $2.15M sold.

Portolan Capital Management first reported a position in RMD in Q4 2013 and held it in 1 quarter. The position peaked at $2.15M in Q4 2013. 318 funds tracked by Wall St. Rank hold RMD as of Q1 2014.

  • Portolan Capital Management reported no remaining ResMed position as of Q1 2014 after selling out during the quarter.
  • Portolan Capital Management sold 45,745 ResMed shares in Q1 2014, an estimated $2.15M.
  • Portolan Capital Management first reported a position in ResMed in Q4 2013 and held it in 1 quarter.
  • Portolan Capital Management's ResMed position peaked at $2.15M in Q4 2013.
  • 318 funds tracked by Wall St. Rank held ResMed as of Q1 2014.

Based on Portolan Capital Management's 13F filing for Q1 2014, filed 15 May 2014.